Litigation Details for BRACCO DIAGNOSTICS INC. v. MAIA PHARMACEUTICALS, INC. (D.N.J. 2017)
✉ Email this page to a colleague
BRACCO DIAGNOSTICS INC. v. MAIA PHARMACEUTICALS, INC. (D.N.J. 2017)
| Docket | ⤷ Start Trial | Date Filed | 2017-12-14 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 15:1126 Patent Infringement | Assigned To | Peter G. Sheridan |
| Jury Demand | None | Referred To | |
| Patents | 6,803,046 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in BRACCO DIAGNOSTICS INC. v. MAIA PHARMACEUTICALS, INC.
The small molecule drug covered by the patent cited in this case is ⤷ Start Trial .
Details for BRACCO DIAGNOSTICS INC. v. MAIA PHARMACEUTICALS, INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-12-14 | 85 | concerning United States Patent No. 6,803,046 (the “046 Patent”). The ‘046 Patent is listed to market and…eight amino acids bound together. (‘046 Patent at 1:9-16). The patent also claims five other ingredients:…It is a ‘bedrock principle’ of patent law that ‘the claims of a patent define the invention to which …invention. (‘046 Patent at 11:29-63 (emphasis added)). In addition, example 3 of the patent indicates that…parties dispute the meaning of three terms in the patent: (1) buffer; (2) surfactant/solubilizer; and (3 | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
